GB Sciences, Inc. (GBLX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.41 Million USD | 13.82% |
| 2022 | 4.75 Million USD | 9.85% |
| 2021 | 4.33 Million USD | -64.72% |
| 2020 | 12.27 Million USD | -14.97% |
| 2019 | 14.44 Million USD | 12.23% |
| 2018 | 12.86 Million USD | 52.85% |
| 2017 | 8.41 Million USD | 82.91% |
| 2016 | 4.6 Million USD | 4.35% |
| 2015 | 4.41 Million USD | 265.96% |
| 2014 | 1.2 Million USD | -22.32% |
| 2013 | 1.55 Million USD | 29.68% |
| 2012 | 1.19 Million USD | -5.77% |
| 2011 | 1.26 Million USD | -10.58% |
| 2010 | 1.41 Million USD | 32.81% |
| 2009 | 1.06 Million USD | 196.93% |
| 2008 | 359.98 Thousand USD | 65.82% |
| 2007 | 217.09 Thousand USD | -61.12% |
| 2006 | 558.33 Thousand USD | 129.07% |
| 2005 | 243.73 Thousand USD | 832.68% |
| 2004 | 26.13 Thousand USD | -9.21% |
| 2003 | 28.78 Thousand USD | 1781.37% |
| 2002 | 1530.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q4 | 5.41 Million USD | 8.48% |
| 2023 FY | 5.41 Million USD | 13.82% |
| 2023 Q2 | 4.92 Million USD | 0.36% |
| 2023 Q3 | 4.99 Million USD | 1.36% |
| 2023 Q1 | 4.9 Million USD | 3.15% |
| 2022 Q3 | 4.4 Million USD | 2.15% |
| 2022 Q1 | 4.5 Million USD | 4.01% |
| 2022 Q4 | 4.75 Million USD | 8.09% |
| 2022 Q2 | 4.31 Million USD | -4.34% |
| 2022 FY | 4.75 Million USD | 9.85% |
| 2021 Q1 | 12.36 Million USD | 0.66% |
| 2021 FY | 4.33 Million USD | -64.72% |
| 2021 Q4 | 4.33 Million USD | -12.87% |
| 2021 Q2 | 12.46 Million USD | 0.88% |
| 2021 Q3 | 4.97 Million USD | -60.12% |
| 2020 Q2 | 16.6 Million USD | 3.63% |
| 2020 Q4 | 12.27 Million USD | -3.65% |
| 2020 FY | 12.27 Million USD | -14.97% |
| 2020 Q1 | 16.02 Million USD | 10.95% |
| 2020 Q3 | 12.74 Million USD | -23.24% |
| 2019 Q2 | 15.52 Million USD | 4.49% |
| 2019 Q1 | 14.85 Million USD | 15.46% |
| 2019 Q3 | 12.6 Million USD | -18.83% |
| 2019 Q4 | 14.44 Million USD | 14.6% |
| 2019 FY | 14.44 Million USD | 12.23% |
| 2018 Q2 | 8.39 Million USD | 0.31% |
| 2018 FY | 12.86 Million USD | 52.85% |
| 2018 Q4 | 12.86 Million USD | 14.24% |
| 2018 Q3 | 11.26 Million USD | 34.11% |
| 2018 Q1 | 8.37 Million USD | -0.53% |
| 2017 Q2 | 7.49 Million USD | 69.18% |
| 2017 Q1 | 4.43 Million USD | -3.73% |
| 2017 FY | 8.41 Million USD | 82.91% |
| 2017 Q4 | 8.41 Million USD | 6.28% |
| 2017 Q3 | 7.92 Million USD | 5.68% |
| 2016 Q2 | 7.24 Million USD | 71.46% |
| 2016 FY | 4.6 Million USD | 4.35% |
| 2016 Q1 | 4.22 Million USD | -4.26% |
| 2016 Q4 | 4.6 Million USD | -16.05% |
| 2016 Q3 | 5.48 Million USD | -24.29% |
| 2015 Q1 | 3.42 Million USD | 184.45% |
| 2015 Q4 | 4.41 Million USD | 23.18% |
| 2015 Q2 | 2.84 Million USD | -17.13% |
| 2015 Q3 | 3.58 Million USD | 26.03% |
| 2015 FY | 4.41 Million USD | 265.96% |
| 2014 Q1 | 553.31 Thousand USD | -64.33% |
| 2014 FY | 1.2 Million USD | -22.32% |
| 2014 Q4 | 1.2 Million USD | 122.82% |
| 2014 Q3 | 540.87 Thousand USD | 1178.84% |
| 2014 Q2 | 42.29 Thousand USD | -92.36% |
| 2013 Q1 | 1.25 Million USD | 5.03% |
| 2013 Q3 | 1.14 Million USD | 18.85% |
| 2013 Q2 | 962.61 Thousand USD | -23.38% |
| 2013 Q4 | 1.55 Million USD | 35.6% |
| 2013 FY | 1.55 Million USD | 29.68% |
| 2012 Q3 | 873.92 Thousand USD | -9.34% |
| 2012 Q1 | 930.83 Thousand USD | -26.68% |
| 2012 Q2 | 963.95 Thousand USD | 3.56% |
| 2012 Q4 | 1.19 Million USD | 36.89% |
| 2012 FY | 1.19 Million USD | -5.77% |
| 2011 Q4 | 1.26 Million USD | -27.51% |
| 2011 Q2 | 1.73 Million USD | -1.09% |
| 2011 Q3 | 1.75 Million USD | 1.17% |
| 2011 FY | 1.26 Million USD | -10.58% |
| 2011 Q1 | 1.75 Million USD | 23.27% |
| 2010 FY | 1.41 Million USD | 32.81% |
| 2010 Q4 | 1.41 Million USD | 1.95% |
| 2010 Q1 | 1.29 Million USD | 20.91% |
| 2010 Q2 | 1.43 Million USD | 10.71% |
| 2010 Q3 | 1.39 Million USD | -2.69% |
| 2009 Q4 | 1.06 Million USD | 23.64% |
| 2009 FY | 1.06 Million USD | 196.93% |
| 2009 Q3 | 864.51 Thousand USD | 82.77% |
| 2009 Q2 | 473.01 Thousand USD | 22.37% |
| 2009 Q1 | 386.55 Thousand USD | 7.38% |
| 2008 Q3 | 316.92 Thousand USD | 7.27% |
| 2008 Q4 | 359.98 Thousand USD | 13.59% |
| 2008 Q1 | 271.16 Thousand USD | 24.9% |
| 2008 Q2 | 295.45 Thousand USD | 8.96% |
| 2008 FY | 359.98 Thousand USD | 65.82% |
| 2007 FY | 217.09 Thousand USD | -61.12% |
| 2007 Q4 | 217.09 Thousand USD | -64.51% |
| 2007 Q3 | 611.76 Thousand USD | -6.36% |
| 2007 Q2 | 653.33 Thousand USD | 16.91% |
| 2007 Q1 | 558.81 Thousand USD | 0.09% |
| 2006 Q2 | 438.41 Thousand USD | -12.87% |
| 2006 Q3 | 460.05 Thousand USD | 4.93% |
| 2006 FY | 558.33 Thousand USD | 129.07% |
| 2006 Q4 | 558.33 Thousand USD | 21.36% |
| 2006 Q1 | 503.15 Thousand USD | 106.43% |
| 2005 Q4 | 243.73 Thousand USD | -25.64% |
| 2005 Q3 | 327.77 Thousand USD | 43.09% |
| 2005 FY | 243.73 Thousand USD | 832.68% |
| 2005 Q2 | 229.06 Thousand USD | 86.37% |
| 2005 Q1 | 122.9 Thousand USD | 370.32% |
| 2004 Q1 | 59.07 Thousand USD | 105.24% |
| 2004 Q4 | 26.13 Thousand USD | -92.51% |
| 2004 FY | 26.13 Thousand USD | -9.21% |
| 2004 Q2 | 211.77 Thousand USD | 258.47% |
| 2004 Q3 | 348.98 Thousand USD | 64.79% |
| 2003 Q3 | 38.29 Thousand USD | 54.39% |
| 2003 Q1 | 17.65 Thousand USD | 1054.05% |
| 2003 Q2 | 24.8 Thousand USD | 40.49% |
| 2003 Q4 | 28.78 Thousand USD | -24.84% |
| 2003 FY | 28.78 Thousand USD | 1781.37% |
| 2002 Q2 | 66.43 Thousand USD | -17.07% |
| 2002 Q4 | 1530.00 USD | -95.3% |
| 2002 Q1 | 80.1 Thousand USD | 0.0% |
| 2002 FY | 1530.00 USD | 0.0% |
| 2002 Q3 | 32.56 Thousand USD | -50.98% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -19648.321% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 42.768% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 92.525% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -569.832% |
| Rebus Holdings, Inc. | 5.24 Million USD | -3.349% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 90.82% |
| Qrons Inc. | 1.48 Million USD | -263.909% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -341.812% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 92.769% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -12020.899% |
| Skye Bioscience, Inc. | 14.07 Million USD | 61.502% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 89.837% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 43.461% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1185.097% |
| SQZ Biotechnologies Company | 50.03 Million USD | 89.173% |
| Intellipharmaceutics International Inc. | 12 Million USD | 54.887% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -40.664% |
| Mesoblast Limited | 188.44 Million USD | 97.125% |
| Marizyme, Inc. | 26.67 Million USD | 79.691% |
| Genus plc | 485 Million USD | 98.883% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 7.275% |
| Pharming Group N.V. | 244.07 Million USD | 97.78% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -169.513% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -115.296% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -42.567% |
| ContraFect Corporation | 32.53 Million USD | 83.346% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -173.433% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -41.537% |
| IMV Inc. | 37.93 Million USD | 85.718% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 54.004% |
| MultiCell Technologies, Inc. | 1617.67 USD | -334798.774% |
| ONE Bio Corp. | 27.49 Million USD | 80.297% |
| Accustem Sciences Inc. | 1.07 Million USD | -401.979% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 93.002% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -156.141% |
| Q BioMed Inc. | 8.13 Million USD | 33.387% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 93.468% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -5.276% |
| Biomind Labs Inc. | 1.49 Million USD | -261.505% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 95.437% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 40.086% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 70.562% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -277.83% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -3712.63% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2593.747% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 5.713% |
| Alpha Cognition Inc. | 7.16 Million USD | 24.386% |
| HST Global, Inc. | 593.59 Thousand USD | -812.672% |
| CSL Limited | 18.62 Billion USD | 99.971% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -330.24% |
| Halberd Corporation | 728.71 Thousand USD | -643.436% |
| Enzolytics Inc. | 365.26 Million USD | 98.517% |
| Agentix Corp. | 2.51 Million USD | -115.791% |
| Resverlogix Corp. | 67.39 Million USD | 91.962% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -545.922% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.782% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -216.077% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 78.107% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 54.486% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -47.812% |
| AVAX Technologies, Inc. | 3.99 Million USD | -35.651% |
| Zenith Capital Corp. | 27.56 Thousand USD | -19550.901% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.591% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2170.047% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -45.075% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -695.724% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -99.789% |
| Kadimastem Ltd | 3.5 Million USD | -54.572% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -7994.484% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 89.222% |
| BioStem Technologies, Inc. | 15.9 Million USD | 65.937% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1065.821% |
| LadRx Corporation | 2.2 Million USD | -146.194% |
| Cell Source, Inc. | 15.8 Million USD | 65.726% |
| Regen BioPharma, Inc. | 5.45 Million USD | 0.734% |
| Regen BioPharma, Inc. | 5.45 Million USD | 0.734% |
| NovAccess Global Inc. | 7.86 Million USD | 31.081% |
| Affymax, Inc. | 8.87 Million USD | 38.93% |
| Itoco Inc. | 1.65 Million USD | -227.711% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -164.069% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 10.439% |
| Mobile Lads Corp. | 1.31 Million USD | -312.453% |
| CytoDyn Inc. | 127.89 Million USD | 95.764% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -12860.973% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -245.865% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 50.951% |
| SYBLEU INC | 681.41 Thousand USD | -695.047% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 11.215% |
| International Stem Cell Corporation | 5.27 Million USD | -2.664% |
| Bioxytran, Inc. | 3.24 Million USD | -66.72% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -765.689% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -17.336% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 86.785% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 75.668% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -167.483% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 1.103% |
| Neutra Corp. | 973.52 Thousand USD | -456.486% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 81.328% |
| PureTech Health plc | 125.58 Million USD | 95.686% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -44.194% |
| IXICO plc | 1.9 Million USD | -185.091% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 73.61% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.757% |
| CSL Limited | 18.62 Billion USD | 99.971% |
| Cellectis S.A. | 249.36 Million USD | 97.827% |